UBS Adjusts CME Group Price Target as Futures Volumes Decline, CME Plans New Offerings

UBS Group has reduced its price target for CME Group, citing a 3% drop in transaction revenue due to weaker futures trading volumes, particularly in interest rate and energy sectors. Despite this, UBS maintained a Neutral rating on the stock. Concurrently, CME Group announced upcoming launches of new futures and options contracts for lean beef trim and single-stock futures, pending regulatory approval.